

World Journal of *Gastrointestinal Surgery*

World J Gastrointest Surg 2023 April 27; 15(4): 495-744



Contents

Monthly Volume 15 Number 4 April 27, 2023

REVIEW

- 495** Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar A, Gautam V, Sandhu A, Rawat K, Sharma A, Saha L
- 520** Harnessing interventions during the immediate perioperative period to improve the long-term survival of patients following radical gastrectomy
Liu LB, Li J, Lai JX, Shi S

MINIREVIEWS

- 534** Nutrition in acute pancreatitis
Gopi S, Saraya A, Gunjan D
- 544** Surgical treatment for recurrent hepatocellular carcinoma: Current status and challenges
Wang D, Xiao M, Wan ZM, Lin X, Li QY, Zheng SS
- 553** The spectrum of pneumatosis intestinalis in the adult. A surgical dilemma
Tropeano G, Di Grezia M, Puccioni C, Bianchi V, Pepe G, Fico V, Altieri G, Brisinda G
- 566** Surgical aspects of small intestinal neuroendocrine tumors
Kupietzky A, Dover R, Mazeh H
- 578** Tumor budding in gastric cancer
Xiao SM, Li J
- 592** Initial management of suspected biliary injury after laparoscopic cholecystectomy
Siiiki A, Ahola R, Vaalavuo Y, Antila A, Laukkanen J

ORIGINAL ARTICLE

Basic Study

- 600** Acinous cell AR42J-derived exosome miR125b-5p promotes acute pancreatitis exacerbation by inhibiting M2 macrophage polarization *via* PI3K/ AKT signaling pathway
Zheng Z, Cao F, Ding YX, Lu JD, Fu YQ, Liu L, Guo YL, Liu S, Sun HC, Cui YQ, Li F

Case Control Study

- 621** Skeletal muscle mass and quality before preoperative chemotherapy influence postoperative long-term outcomes in esophageal squamous cell carcinoma patients
Ichinohe D, Muroya T, Akasaka H, Hakamada K

Retrospective Study

- 634 *In situ* subtotal spleen resection combined with selective pericardial devascularization for the treatment of portal hypertension

Li HL, Ning SL, Gao YJ, Zhou T, Chen YX

- 643 Risk factors for blood transfusion and its prognostic implications in curative gastrectomy for gastric cancer

Kawakami LE, Bonomi PB, Pereira MA, Carvalho FO, Ribeiro Jr U, Zilberstein B, Sampaio LR, Carneiro-D'Albuquerque LA, Ramos MFKP

Clinical Trials Study

- 655 Endoscopic ultrasound-guided intraportal injection of autologous bone marrow in patients with decompensated liver cirrhosis: A case series

Zheng SP, Deng AJ, Zhou JJ, Yuan LZ, Shi X, Wang F

- 664 Computed tomography perfusion in differentiating portal hypertension: A correlation study with hepatic venous pressure gradient

Dong J, Zhang Y, Wu YF, Yue ZD, Fan ZH, Zhang CY, Liu FQ, Wang L

Observational Study

- 674 Ligamentum teres hepatis as a graft for portal and/or superior mesenteric vein reconstruction: From bench to bedside

Zhu WT, Wang HT, Guan QH, Zhang F, Zhang CX, Hu FA, Zhao BL, Zhou L, Wei Q, Ji HB, Fu TL, Zhang XY, Wang RT, Chen QP

- 687 Efficacy and safety analysis of transarterial chemoembolization and transarterial radioembolization in advanced hepatocellular carcinoma descending hepatectomy

Feng R, Cheng DX, Song T, Chen L, Lu KP

Prospective Study

- 698 Effectiveness of a new approach to minimally invasive surgery in palliative treatment of patients with distal malignant biliary obstruction

Susak YM, Markulan LL, Lobanov SM, Palitsya RY, Rudyk MP, Skivka LM

Randomized Controlled Trial

- 712 External use of mirabilite to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis in children: A multicenter randomized controlled trial

Zeng JQ, Zhang TA, Yang KH, Wang WY, Zhang JY, Hu YB, Xiao J, Gu ZJ, Gong B, Deng ZH

SYSTEMATIC REVIEWS

- 723 The global epidemiology of upper and lower gastrointestinal bleeding in general population: A systematic review

Saydam SS, Molnar M, Vora P

CASE REPORT

- 740 Idiopathic colopleural fistula presenting with lung abscess and refractory empyema: A case report

Wang CL, Cheng KC

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Surgery*, Sami Akbulut, MD, PhD, Full Professor, Department of Surgery and Liver Transplant Institute, Inonu University Faculty of Medicine, Malatya 44280, Turkey. akbulutsami@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Surgery* (WJGS, *World J Gastrointest Surg*) is to provide scholars and readers from various fields of gastrointestinal surgery with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGS mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal surgery and covering a wide range of topics including biliary tract surgical procedures, biliopancreatic diversion, colectomy, esophagectomy, esophagostomy, pancreas transplantation, and pancreatectomy, etc.

INDEXING/ABSTRACTING

The WJGS is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJGS as 2.505; IF without journal self cites: 2.473; 5-year IF: 3.099; Journal Citation Indicator: 0.49; Ranking: 104 among 211 journals in surgery; Quartile category: Q2; Ranking: 81 among 93 journals in gastroenterology and hepatology; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Rui-Rui Wu; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL

World Journal of Gastrointestinal Surgery

ISSN

ISSN 1948-9366 (online)

LAUNCH DATE

November 30, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Peter Schemmer

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-9366/editorialboard.htm>

PUBLICATION DATE

April 27, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Surgical treatment for recurrent hepatocellular carcinoma: Current status and challenges

Di Wang, Min Xiao, Zhen-Miao Wan, Xin Lin, Qi-Yong Li, Shu-Sen Zheng

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C, C, C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Elshimi E, Egypt;
Kanno H, Japan

Received: December 6, 2022

Peer-review started: December 6, 2022

First decision: December 19, 2022

Revised: January 5, 2023

Accepted: March 21, 2023

Article in press: March 21, 2023

Published online: April 27, 2023



Di Wang, Zhen-Miao Wan, Division of Hepatobiliary and Pancreatic Surgery, Zhejiang Chinese Medical University, Hangzhou 310000, Zhejiang Province, China

Di Wang, Min Xiao, Zhen-Miao Wan, Xin Lin, Qi-Yong Li, Shu-Sen Zheng, Division of Hepatobiliary and Pancreatic Surgery, Jinan Microecological Biomedicine Shandong Laboratory, Jinan 250000, Shandong Province, China

Min Xiao, Xin Lin, Qi-Yong Li, Shu-Sen Zheng, Division of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou 310000, Zhejiang Province, China

Corresponding author: Shu-Sen Zheng, MD, PhD, Chief Physician, Doctor, Division of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, No. 848 Dongxin Road, Hangzhou 310000, Zhejiang Province, China. shusenzheng@zju.edu.cn

Abstract

Primary liver cancer is the sixth most commonly diagnosed cancer and was the third leading cause of cancer deaths worldwide in 2020. It includes hepatocellular carcinoma (HCC) (representing 75%-85% of cases), intrahepatic cholangiocarcinoma (representing 10%-15% of cases), and other rare types. The survival rate of patients with HCC has risen with improved surgical technology and perioperative management in recent years; however, high tumor recurrence rates continue to limit long-term survival, even after radical surgical resection (exceeding 50% recurrence). For resectable recurrent liver cancer, surgical removal [either salvage liver transplantation (SLT) or repeat hepatic resection] remains the most effective therapy that is potentially curative for recurrent HCC. Thus, here, we introduce surgical treatment for recurrent HCC. Areas Covered: A literature search was performed for recurrent HCC using Medline and PubMed up to August 2022. Expert commentary: In general, long-term survival after the resection of recurrent liver cancer is usually beneficial. SLT has equivalent outcomes to primary liver transplantation for unresectable recurrent illness in a selected group of patients; however, SLT is constrained by the supply of liver grafts. SLT seems to be inferior to repeat liver resection when considering operative and postoperative results but has the major advantage of disease-free survival. When considering the similar overall survival rate and the current situation of donor shortages, repeat liver resection remains an important option for recurrent HCC.

Key Words: Hepatocellular carcinoma; Repeated liver resection; Salvage liver transplantation; Primary liver cancer

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This article reviews the previous literature reports on the statistics of surgical treatment of recurrent liver cancer, mainly including re-hepatectomy and salvage liver transplantation. This article focuses on the analysis and comparison of the respective advantages and disadvantages of these two methods and proposes a future vision.

Citation: Wang D, Xiao M, Wan ZM, Lin X, Li QY, Zheng SS. Surgical treatment for recurrent hepatocellular carcinoma: Current status and challenges. *World J Gastrointest Surg* 2023; 15(4): 544-552

URL: <https://www.wjgnet.com/1948-9366/full/v15/i4/544.htm>

DOI: <https://dx.doi.org/10.4240/wjgs.v15.i4.544>

INTRODUCTION

In every nation on earth, cancer is the main cause of mortality and a significant roadblock to raising life expectancy[1]. In 2020, primary liver cancer, which is the sixth most often diagnosed cancer, was the third greatest cause of cancer deaths globally[2]. It includes hepatocellular carcinoma (HCC) (representing 75%-85% of cases), intrahepatic cholangiocarcinoma (representing 10%-15% of cases), and other rare types. At present, the diagnosis of HCC is usually based on the standards established by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases[3]. Curative treatment for HCC modalities includes resection, ablative therapies (such as radiofrequency ablation, percutaneous ethanol injection, and liver transplantation), and palliative treatment [including trans-arterial chemoembolization (TACE) and targeted systemic chemotherapy with sorafenib][4]. Guidelines from countries worldwide recommend surgical resection as the preferred course of treatment for individuals with resectable tumors[5-7]. With more advanced surgical techniques and postoperative care in recent years, the survival rate of patients with HCC has increased, although long-term survival following surgical resection is still hampered by the high tumor recurrence rate[8-11]. Even after surgical resection, which is thought to be the most radical therapy, the recurrence rate has been reported to exceed 50%[12-14].

Recurrent cancers in liver remains have been treated using the therapeutic techniques frequently utilized for original tumors, such as TACE, radiotherapy, local ablative therapy, surgical resection, and liver transplantation[15]. Nonsurgical options are commonly indicated for the treatment of recurrent HCC since second procedures are frequently unacceptably risky due to the presence of multiple tumors or inadequately preserved liver function. The most effective treatment that may be curative for recurrent HCC remains surgical excision [either salvage liver transplantation (SLT) or repeat hepatic resection] for resectable recurrent liver cancer[16]. Here, we aimed to introduce surgical treatment for recurrent HCC.

RECURRENCE OF HCC

The recurrence of HCC can be either intrahepatic or extrahepatic. The rate of extrahepatic recurrence is far lower compared to that of intrahepatic recurrence. Extrahepatic metastasis is usually considered a late systemic disease[17]. Therefore, patients with extrahepatic recurrence usually receive systemic chemotherapy or supportive treatment only[18-20]. The most frequent kind of recurrent HCC, which is observed in 68%-96% of cases, is intrahepatic recurrence[17,21-23]. Clinically, intrahepatic recurrence is generally attributed to two alternative mechanisms: (1) Intrahepatic metastasis from a primary site; and (2) metachronous multicentric carcinogenesis[24]. Numerous studies have demonstrated that microvascular invasion is a major predictor of tumor recurrence and overall survival (OS) following surgical resection and liver transplantation for HCC[25-29]. According to several studies, there is a larger likelihood of microvascular invasion when there is a higher tumor burden (measured in terms of size and quantity)[30,31]. The alpha-fetoprotein level, transfusion, tumor grade, macroscopic portal vein involvement, the existence of satellite nodules, and positive surgical margin are additional recurrence predictors noted by other research[27,32].

REPEATED LIVER RESECTION

A treatment that may be curative for liver tumors is hepatic resection, which gives patients a possibility of long-term survival. Several treatment centers currently recommend repeating hepatectomy as the first line of therapy for recurrent HCC because it is secure and has comparable survival rates to the first hepatectomy[17]. The majority of patients with intrahepatic recurrence, however, are thought to be unsuitable for repeat hepatectomy[33]. At present, there is no uniform, standard for indicating re-hepatectomy; however, the basic principle is the same. Specifically, currently used standards include a Grade A Child-Pugh score of liver function, sufficient volume of residual liver, recurrent tumors are single or multiple nodules confined to one lobe or liver segment, and there is no invasion of the main blood vessels and bile ducts of the hepatic portal[34]. Repeat hepatectomy is performed 7%-30% of the time to treat HCC recurrence[33,35]. The multifocality, location, and degree of cirrhosis have all been linked to the poor incidence of resectability in individuals with intrahepatic recurrence[36].

The first study of second hepatic resections for recurrent HCC in nine patients without single surgical mortality was reported by Nagasue *et al*[37] in 1986. This study showed that repeated hepatic resection was a feasible and beneficial therapeutic approach for patients with recurrent HCCs in the liver residual [37]. Subsequently, several studies reported the feasibility of repeated hepatectomies for intrahepatic HCC recurrence, with it increasing survival time with no significant increase in morbidity and mortality rates[38-41]. According to Wu *et al*[41], therapy of recurrent HCC with a second hepatectomy was successful, even in cases of the disease's second and third occurrences.

The surgical procedure for liver resection is still challenging and associated with complications[20,42,43]. The more times a hepatectomy is performed, the more challenging resection is[19,38,39,44-49]. Compared to HCC patients that undergo primary hepatectomy, repeat hepatectomy has a higher risk of complications. Such complications include intra-abdominal adhesions caused by the previous hepatectomy, poorer systemic conditions, progressive deterioration of liver function in patients with cirrhosis, inconsistent liver regeneration, and new growth of intrahepatic vascular structures since the previous hepatectomy[41].

Laparoscopic hepatectomy is now frequently accepted as a minimally invasive method for curing HCC[50-52]. When compared to open liver resection, laparoscopic liver surgery is consistently associated with lower complication rates, less intraoperative bleeding, and a shorter hospital stay[53]. For patients with recurring HCC, Chan *et al*[54] demonstrated that laparoscopic re-resection is possible and secure. The authors identified no discernible differences in patient characteristics, preoperative liver function, and tumor features between laparoscopic and open groups, with the laparoscopic group's perioperative blood loss being considerably reduced (100 *vs* 314 mL; $P = 0.014$). Moreover, both the morbidity rate (18.2 *vs* 4.5%; $P = 0.199$) and the length of hospitalization (6 *vs* 5 d; $P = 0.831$) were comparable. Laparoscopic and open groups had three-year OS rates of 60.0% and 89.3%, respectively ($P = 0.279$)[54].

Nonetheless, existing data cannot confirm whether repeated hepatectomy is superior to other methods used to treat recurrent HCC. Due to selection bias, the prognosis of repeated hepatectomy compared with other treatment methods might not be valid. Patients that do not undergo repeated hepatectomy might have poor liver function reserves, or tumor recurrence might be too serious. Repeated hepatectomy as well as alternative treatment methods for recurrent HCC require prospective randomized studies. For patients with primary and secondary liver recurrences, repeated hepatectomy is still the preferred treatment for recurrent liver cancer.

SLT

Since the first attempted human liver transplantation was reported in 1963 by Starzl *et al*[55], surgical techniques and perioperative patient care for liver transplantation have improved, resulting in it now being a common and routine operation. The use of SLT to treat recurrent HCC following primary liver resection has recently been suggested as a way to increase the duration that HCC patients survive[56]. SLT was initially proposed by Majno *et al*[56] and involves the resection or ablation of the primary tumor, followed by transplantation when recurrence develops.

SLT has gained popularity as surgical technology has advanced because of its effectiveness, which is on par with primary transplantation[57,58]. SLT makes it possible for patients to have prompt, efficient, and secure therapy for HCC. Hepatectomy patients who do not have recurrence are exempt from the need for liver transplantation, which helps to address the scarcity of organ donors. SLT is thought to be comparable to primary liver transplantation and has a respectable long-term survival rate, despite the fact that HCC tends to have more aggressive tumor biology[59-61]. In comparison to repeated liver resection or other salvage therapy for HCC recurrence, SLT may also result in higher long-term survival [62-64]. This suggestion was supported in the published meta-analysis by Zheng *et al*[65].

The indications for SLT differ among studies, especially regarding the acceptable extent of recurrent HCC lesions[48,66-68]. It is still controversial what definition is meant by "transplantability criteria in SLT," which refers to standards identifying the individuals who would benefit most from

transplantation for HCC recurrence following hepatectomy[60,69]. The majority of research concurs that a decent post-SLT survival rate may be attained using the Milan criteria for patients with limited recurrence[70]. Zhang *et al*[71] studied the Milan criteria, the University of California San Francisco (UCSF) criteria, and the model for end-stage liver disease (MELD) score to find predictors for SLT. According to the author, the MELD score, Milan, and UCSF criteria were effective at estimating the outcome of SLT. The author emphasized in particular that SLT could be conducted with a favorable prognosis when the Milan criteria were met by the recurring HCC lesions. De Haas claimed that patients with better MELD scores, no preoperative TACE, no postoperative complications following the first hepatectomy, and low T-stage in the excised specimen are the best candidates for SLT[72]. There was no discernible difference in OS and disease-free survival (DFS) rates between the SLT and primary liver transplantation (PLT) groups when Liu *et al*[73] examined the effectiveness of SLT for patients with recurrent HCC following hepatectomy using UCSF criteria.

Previous studies showed that the average operating time lasts 7-10 h[74-76], with an average blood loss of 1.5-3 L[74-77]. Hu *et al*[76] observed a variety of postoperative complications in their review of 888 SLT cases, including intra-abdominal collection or abscesses and intra-abdominal hemorrhage (31% and 7% of patients, respectively). The authors also recorded postoperative infections in 30% of patients. There were 18%, 3%, and 4%, respectively, of biliary complications, renal failure, and vascular problems [76]. The range of postoperative mortality was 2.1% to 11.8%[74,77]. The rates of five-year DFS (37.8%-86%)[68,76-79] and five-year OS (46.6%-88%)[68,74-77] are very different among studies.

COMPARATIVE STUDY OF REPEATED LIVER RESECTION AND SLT

The statistics on survival after the surgical treatment of recurrent liver cancer in recent years are shown in Table 1. SLT and re-resection for recurrent HCC had comparable survival results, according to a cohort study by Chan *et al*[80]. The authors also demonstrated a relationship between poor DFS and preoperative serum alpha-fetoprotein (AFP) levels and the time to recurrence. SLT may thus be more suitable for patients who have a late recurrence and low serum AFP levels[80]. Furthermore, Lim *et al* [81] showed that five-year OS was similar for SLT and second resection strategies; however, SLT achieved better DFS, which might be attributed to several factors. To be more precise, SLT may: (1) Use complete hepatectomy to achieve the safest resection margin; (2) remove clinically undetectable distant micrometastases from the leftover liver; and (3) treat underlying liver disease, avoiding the emergence of HCC in the liver that remains[81]. Patients in the SLT group also had fewer procedures and treatments, and likely had a better quality of life compared to those in the second resection group[81]. Kostakis *et al*[82] backed up this claim by demonstrating that SLT has a clear benefit over recurrent liver resection (RLR) in terms of DFS. The authors did note, however, that SLT seemed to yield less favorable surgical and postoperative outcomes than RLR.

Re-resection has two clear advantages over SLT. First, the technique is not overly complex, and it is a therapy option that is readily available. Second, there are no opportunistic infection risks or immunosuppression-related risks[15]. A recommendation for the second resection first and SLT for unresectable recurrent illness may lessen the strain on the organ donor pool without reducing the likelihood of long-term survival[15].

CONCLUSION

In general, after the second resection for recurrent HCC, long-term survival rates are favorable. SLT has equivalent outcomes to primary liver transplantation for unresectable recurrent illness in a selected group of patients; however, SLT is constrained by the supply of liver grafts. In terms of surgical and postoperative outcomes, SLT appears to be inferior to repeat liver resection; nevertheless, it offers a sizable benefit in terms of DFS compared to repeat liver resection. Repeat liver resection is still an essential option for treating recurrent HCC when taking into account the similar OS rate and current donor scarcity.

The most crucial method for extending patients' life following hepatectomy at the moment is the aggressive treatment of postoperative intrahepatic recurrence. The outcome for long-term survival following resection of recurring liver cancer is generally favorable for resectable cancer. SLT offers outcomes comparable to primary liver transplantation for unresectable recurring illnesses but is constrained by the lack of liver transplant donor availability. Recent advances in systemic and loco-regional treatments for patients with unresectable and advanced HCC have resulted in improved response rates[83]. Consequently, selected patients with initially unresectable HCC have been given the opportunity to achieve adequate tumor downstaging to undergo surgical resection, a "conversion therapy" strategy[83]. For originally unresectable recurrent liver cancer, the potential of "conversion therapy" in transforming some unresectable patients into resectable patients is worth further clinical research. In addition to surgical treatment, TACE, RF ablation, and other forms of local ablation (such as microwave and high-intensity focused ultrasound) are used to treat recurrent liver cancer. It is still

Table 1 Statistics showing survival after surgical treatment of recurrent liver cancer based on published studies spanning 1989 to 2017

Ref.	Study design	Study period	n	Treatment	DFS rate (1-, 3-, 5-yr)	OS rate (1-, 3-, 5-yr)	DSS rate (1-, 3-, 5-yr)
Guerrini <i>et al</i> [84], 2014	Retrospectivecohort	2000-2011	28	SLT	95.1%, 80.6%, 80.6%	85.1%, 66.4%, 49.2%	NA
Qu <i>et al</i> [75], 2015	Retrospectivecohort	2000-2011	111	SLT	NA	75.5%, 56.3%, 49.1%	NA
Yamashita <i>et al</i> [62], 2015	Retrospectivecohort	1989-2012	13	SLT	NA, NA, 81%	NA, NA, 75%	NA
Lim <i>et al</i> [81], 2017	Retrospectivecohort	1994-2011	17	SLT	NA, 80%, 72%	NA, 71%, 71%	NA
Chan <i>et al</i> [3], 2019	Retrospectivecohort	2005-2017	59	SLT	84.8%, 68.2%, 68.2%	NA	95.7%, 74.4%, 66.7%
Yoon <i>et al</i> [85], 2022	Retrospectivecohort	2005-2017	42	SLT	91.6%, 78.6%, 76.8%	NA	98.8%, 90.7%, 87.0%
Minagawa <i>et al</i> [47], 2003	Retrospectivecohort	1994-2000	67	RLR	50%, 21%, 17%	93%, 70%, 56%	NA
Itamoto <i>et al</i> [38], 2007	Retrospectivecohort	1990-2004	84	RLR	56%, 25%, 10%	88%, 67%, 50%	NA
Wu <i>et al</i> [41], 2009	Retrospectivecohort	1990-2007	149	RLR	NA, NA, 31.8%	NA, NA, 56.4%	NA
Faber <i>et al</i> [86], 2011	Retrospectivecohort	1990-2009	27	RLR	NA	96%, 70%, 42%	NA
Yamashita <i>et al</i> [62], 2015	Retrospectivecohort	1989-2012	146	RLR	NA, NA, 16%	NA, NA, 61%	NA
Lim <i>et al</i> [81], 2017	Retrospectivecohort	1994-2011	80	RLR	NA, 22%, 18%	NA, 82%, 71%	NA

DFS: Disease-free survival; OS: Overall survival; DSS: Disease-specific survival; SLT: Salvage liver transplantation; RLR: Repeated liver resection; NA: Not available.

necessary to continue exploring how to formulate a reasonable treatment plan on the premise of fully evaluating the status of patients.

Most existing reports on the surgical treatment of recurrent liver cancer are retrospective, with limitations, such as case selection bias, to varying degrees. Thus, it is necessary to raise the standard of clinical evidence-based medicine in the surgical treatment of recurring liver cancer. More clinical studies, especially randomized prospective studies, are required to confirm the safety and effectiveness of the surgical treatment of recurring liver cancer, and to improve guidance on the surgical treatment of recurring liver cancer.

FOOTNOTES

Author contributions: All authors contributed to data collection, analysis, drafting, or revising the article, have agreed on the journal to which the article will be submitted, gave final approval to the version to be published, and agree to be responsible for all aspects of the work.

Supported by the Jinan Microecological Biomedicine Shandong Laboratory, No. JNL-2022022C; and the Health Commission of Zhejiang Province, No. JBZX-202004.

Conflict-of-interest statement: The authors report no conflicts of interest in this work.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Shu-Sen Zheng 0000-0003-1459-8261.

S-Editor: Yan JP

L-Editor: A

P-Editor: Yan JP

REFERENCES

- 1 **Bray F**, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. *Cancer* 2021; **127**: 3029-3030 [PMID: [34086348](#) DOI: [10.1002/encr.33587](#)]
- 2 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: [33538338](#) DOI: [10.3322/caac.21660](#)]
- 3 **Chan KM**, Wu TH, Cheng CH, Lee CF, Wu TJ, Chou HS, Lee WC. Advantage of early liver transplantation whenever indicated for hepatocellular carcinoma recurrence after primary liver resection. *Biomed J* 2019; **42**: 335-342 [PMID: [31783994](#) DOI: [10.1016/j.bj.2019.04.001](#)]
- 4 **Cabrera R**, Nelson DR. Review article: the management of hepatocellular carcinoma. *Aliment Pharmacol Ther* 2010; **31**: 461-476 [PMID: [19925500](#) DOI: [10.1111/j.1365-2036.2009.04200.x](#)]
- 5 **Clark T**, Maximin S, Meier J, Pokharel S, Bhargava P. Hepatocellular Carcinoma: Review of Epidemiology, Screening, Imaging Diagnosis, Response Assessment, and Treatment. *Curr Probl Diagn Radiol* 2015; **44**: 479-486 [PMID: [25979220](#) DOI: [10.1067/j.cpradiol.2015.04.004](#)]
- 6 **Chen LT**, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. *Ann Oncol* 2020; **31**: 334-351 [PMID: [32067677](#) DOI: [10.1016/j.annonc.2019.12.001](#)]
- 7 **Cholangiocarcinoma Working Group**. Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part II: Treatment. *Dig Liver Dis* 2020; **52**: 1430-1442 [PMID: [32952071](#) DOI: [10.1016/j.dld.2020.08.030](#)]
- 8 **Yang Y**, Nagano H, Ota H, Morimoto O, Nakamura M, Wada H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Dono K, Umeshita K, Nakamori S, Wakasa K, Sakon M, Monden M. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. *Surgery* 2007; **141**: 196-202 [PMID: [17263976](#) DOI: [10.1016/j.surg.2006.06.033](#)]
- 9 **Tang ZY**, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, Ji XN, Liu H, Xia JL, Wu ZQ, Fan J, Ma ZC, Zhou XD, Lin ZY, Liu KD. A decade's studies on metastasis of hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2004; **130**: 187-196 [PMID: [14685850](#) DOI: [10.1007/s00432-003-0511-1](#)]
- 10 **Zhou SL**, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, Huang XW, Fan J, Zhou J. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. *Hepatology* 2012; **56**: 2242-2254 [PMID: [22711685](#) DOI: [10.1002/hep.25907](#)]
- 11 **Zhou SL**, Yin D, Hu ZQ, Luo CB, Zhou ZJ, Xin HY, Yang XR, Shi YH, Wang Z, Huang XW, Cao Y, Fan J, Zhou J. A Positive Feedback Loop Between Cancer Stem-Like Cells and Tumor-Associated Neutrophils Controls Hepatocellular Carcinoma Progression. *Hepatology* 2019; **70**: 1214-1230 [PMID: [30933361](#) DOI: [10.1002/hep.30630](#)]
- 12 **Zhou XD**, Yu YQ, Tang ZY, Yang BH, Lu JZ, Lin ZY, Ma ZC, Xu DB, Zhang BH, Zheng YX. Surgical treatment of recurrent hepatocellular carcinoma. *Hepatogastroenterology* 1993; **40**: 333-336 [PMID: [8406302](#)]
- 13 **Nagasue N**, Uchida M, Makino Y, Takemoto Y, Yamanoi A, Hayashi T, Chang YC, Kohno H, Nakamura T, Yukaya H. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. *Gastroenterology* 1993; **105**: 488-494 [PMID: [8392955](#) DOI: [10.1016/0016-5085\(93\)90724-q](#)]
- 14 **Suenaga M**, Sugiura H, Kokuba Y, Uehara S, Kurumiya T. Repeated hepatic resection for recurrent hepatocellular carcinoma in eighteen cases. *Surgery* 1994; **115**: 452-457 [PMID: [7513088](#)]
- 15 **Dai WC**, Cheung TT. Strategic overview on the best treatment option for intrahepatic hepatocellular carcinoma recurrence. *Expert Rev Anticancer Ther* 2016; **16**: 1063-1072 [PMID: [27548586](#) DOI: [10.1080/14737140.2016.1226136](#)]
- 16 **Rahbari NN**, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J. Hepatocellular carcinoma: current management and perspectives for the future. *Ann Surg* 2011; **253**: 453-469 [PMID: [21263310](#) DOI: [10.1097/SLA.0b013e31820d944f](#)]
- 17 **Tung-Ping Poon R**, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. *Ann Surg* 2000; **232**: 10-24 [PMID: [10862190](#) DOI: [10.1097/0000658-200007000-00003](#)]
- 18 **Kanematsu T**, Matsumata T, Takenaka K, Yoshida Y, Higashi H, Sugimachi K. Clinical management of recurrent hepatocellular carcinoma after primary resection. *Br J Surg* 1988; **75**: 203-206 [PMID: [2832032](#) DOI: [10.1002/bjs.1800750305](#)]
- 19 **Lee PH**, Lin WJ, Tsang YM, Hu RH, Sheu JC, Lai MY, Hsu HC, May W, Lee CS. Clinical management of recurrent hepatocellular carcinoma. *Ann Surg* 1995; **222**: 670-676 [PMID: [7487215](#) DOI: [10.1097/0000658-199511000-00010](#)]
- 20 **Shimada M**, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, Maeda T, Shirabe K, Nishizaki T, Yanaga K, Sugimachi K. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. *Gastroenterology* 1996; **111**: 720-726 [PMID: [8780578](#) DOI: [10.1053/gast.1996.v111.pm8780578](#)]
- 21 **Lau WY**, Lai EC. Hepatocellular carcinoma: current management and recent advances. *Hepatobiliary Pancreat Dis Int* 2008; **7**: 237-257 [PMID: [18522878](#)]
- 22 **El-Serag HB**. Hepatocellular carcinoma. *N Engl J Med* 2011; **365**: 1118-1127 [PMID: [21992124](#) DOI: [10.1056/NEJMra1001683](#)]
- 23 **Forner A**, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet* 2012; **379**: 1245-1255 [PMID: [22353262](#) DOI: [10.1016/S0140-6736\(11\)61347-0](#)]
- 24 **Arii S**, Monden K, Niwano M, Furutani M, Mori A, Mizumoto M, Imamura M. Results of surgical treatment for recurrent hepatocellular carcinoma; comparison of outcome among patients with multicentric carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence. *J Hepatobiliary Pancreat Surg* 1998; **5**: 86-92 [PMID: [9683759](#) DOI: [10.1007/pl00009956](#)]

- 25 **Lim KC**, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, Chung AY, Ooi LL, Tan SB. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. *Ann Surg* 2011; **254**: 108-113 [PMID: 21527845 DOI: 10.1097/SLA.0b013e31821ad884]
- 26 **Benckert C**, Jonas S, Thelen A, Spinelli A, Schumacher G, Heise M, Langrehr J, Neuhaus P. Liver transplantation for hepatocellular carcinoma in cirrhosis: prognostic parameters. *Transplant Proc* 2005; **37**: 1693-1694 [PMID: 15919433 DOI: 10.1016/j.transproceed.2005.03.143]
- 27 **Poon RT**, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. *Ann Surg* 2002; **235**: 373-382 [PMID: 11882759 DOI: 10.1097/0000658-200203000-00009]
- 28 **Shimoda M**, Ghobrial RM, Carmody IC, Anselmo DM, Farmer DG, Yersiz H, Chen P, Dawson S, Durazo F, Han S, Goldstein LI, Saab S, Hiatt J, Busuttil RW. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. *Liver Transpl* 2004; **10**: 1478-1486 [PMID: 15558585 DOI: 10.1002/Lt.20303]
- 29 **Yamamoto J**, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, Yamaguchi N, Makuuchi M. Recurrence of hepatocellular carcinoma after surgery. *Br J Surg* 1996; **83**: 1219-1222 [PMID: 8983610]
- 30 **Adachi E**, Maeda T, Kajiyama K, Kinukawa N, Matsumata T, Sugimachi K, Tsuneyoshi M. Factors correlated with portal venous invasion by hepatocellular carcinoma: univariate and multivariate analyses of 232 resected cases without preoperative treatments. *Cancer* 1996; **77**: 2022-2031 [PMID: 8640665 DOI: 10.1002/(sici)1097-0142(19960515)77:10<2022::Aid-encr9>3.0.Co;2-s]
- 31 **Sumie S**, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, Watanabe Y, Kojiro M, Sata M. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. *Ann Surg Oncol* 2008; **15**: 1375-1382 [PMID: 18324443 DOI: 10.1245/s10434-008-9846-9]
- 32 **Roayaie S**, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, Labow DM, Llovet JM, Schwartz ME. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. *Gastroenterology* 2009; **137**: 850-855 [PMID: 19524573 DOI: 10.1053/j.gastro.2009.06.003]
- 33 **Zhou Y**, Sui C, Li B, Yin Z, Tan Y, Yang J, Liu Z. Repeat hepatectomy for recurrent hepatocellular carcinoma: a local experience and a systematic review. *World J Surg Oncol* 2010; **8**: 55 [PMID: 20591196 DOI: 10.1186/1477-7819-8-55]
- 34 **Huang ZY**, Liang BY, Xiong M, Zhan DQ, Wei S, Wang GP, Chen YF, Chen XP. Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China. *Ann Surg Oncol* 2012; **19**: 2515-2525 [PMID: 22395985 DOI: 10.1245/s10434-012-2269-7]
- 35 **Chan DL**, Morris DL, Chua TC. Clinical efficacy and predictors of outcomes of repeat hepatectomy for recurrent hepatocellular carcinoma - a systematic review. *Surg Oncol* 2013; **22**: e23-e30 [PMID: 23535302 DOI: 10.1016/j.suronc.2013.02.009]
- 36 **Kawano Y**, Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, Shibata K, Ohta M, Kitano S. Prognosis of patients with intrahepatic recurrence after hepatic resection for hepatocellular carcinoma: a retrospective study. *Eur J Surg Oncol* 2009; **35**: 174-179 [PMID: 18325724 DOI: 10.1016/j.ejso.2008.01.027]
- 37 **Nagasue N**, Yukaya H, Ogawa Y, Sasaki Y, Chang YC, Niimi K. Second hepatic resection for recurrent hepatocellular carcinoma. *Br J Surg* 1986; **73**: 434-438 [PMID: 2424540 DOI: 10.1002/bjs.1800730606]
- 38 **Itamoto T**, Nakahara H, Amano H, Kohashi T, Ohdan H, Tashiro H, Asahara T. Repeat hepatectomy for recurrent hepatocellular carcinoma. *Surgery* 2007; **141**: 589-597 [PMID: 17462458 DOI: 10.1016/j.surg.2006.12.014]
- 39 **Kakazu T**, Makuuchi M, Kawasaki S, Miyagawa S, Hashikura Y, Kosuge T, Takayama T, Yamamoto J. Repeat hepatic resection for recurrent hepatocellular carcinoma. *Hepatogastroenterology* 1993; **40**: 337-341 [PMID: 8406303]
- 40 **Matsuda M**, Fujii H, Kono H, Matsumoto Y. Surgical treatment of recurrent hepatocellular carcinoma based on the mode of recurrence: repeat hepatic resection or ablation are good choices for patients with recurrent multicentric cancer. *J Hepatobiliary Pancreat Surg* 2001; **8**: 353-359 [PMID: 11521181 DOI: 10.1007/s005340170008]
- 41 **Wu CC**, Cheng SB, Yeh DC, Wang J, P'eng FK. Second and third hepatectomies for recurrent hepatocellular carcinoma are justified. *Br J Surg* 2009; **96**: 1049-1057 [PMID: 19672929 DOI: 10.1002/bjs.6690]
- 42 **Poon RT**, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. *Ann Surg* 1999; **229**: 216-222 [PMID: 10024103 DOI: 10.1097/0000658-199902000-00009]
- 43 **Wu CC**, Cheng SB, Ho WM, Chen JT, Liu TJ, P'eng FK. Liver resection for hepatocellular carcinoma in patients with cirrhosis. *Br J Surg* 2005; **92**: 348-355 [PMID: 15672423 DOI: 10.1002/bjs.4838]
- 44 **Nakajima Y**, Ohmura T, Kimura J, Shimamura T, Misawa K, Matsushita M, Sato N, Une Y, Uchino J. Role of surgical treatment for recurrent hepatocellular carcinoma after hepatic resection. *World J Surg* 1993; **17**: 792-795 [PMID: 8109120 DOI: 10.1007/bf01659099]
- 45 **Kubo S**, Takemura S, Uenishi T, Yamamoto T, Ohba K, Ogawa M, Hai S, Ichikawa T, Kodai S, Shinkawa H, Tanaka H. Second hepatic resection for recurrent hepatocellular carcinoma in patients with chronic hepatitis C. *World J Surg* 2008; **32**: 632-638 [PMID: 18210185 DOI: 10.1007/s00268-007-9365-z]
- 46 **Hu RH**, Lee PH, Yu SC, Dai HC, Sheu JC, Lai MY, Hsu HC, Chen DS. Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. *Surgery* 1996; **120**: 23-29 [PMID: 8693418 DOI: 10.1016/s0039-6060(96)80236-4]
- 47 **Minagawa M**, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. *Ann Surg* 2003; **238**: 703-710 [PMID: 14578733 DOI: 10.1097/01.sla.0000094549.11754.e6]
- 48 **Hwang S**, Lee SG, Moon DB, Ahn CS, Kim KH, Lee YJ, Ha TY, Song GW. Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma. *Liver Transpl* 2007; **13**: 741-746 [PMID: 17457860 DOI: 10.1002/Lt.21157]
- 49 **Adam R**, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H. Liver resection for colorectal metastases: the third hepatectomy. *Ann Surg* 2003; **238**: 871-883; discussion 883 [PMID: 14631224 DOI: 10.1097/01.sla.0000098112.04758.4e]
- 50 **Cheung TT**, Poon RT, Yuen WK, Chok KS, Jenkins CR, Chan SC, Fan ST, Lo CM. Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience.

- Ann Surg* 2013; **257**: 506-511 [PMID: [23299521](#) DOI: [10.1097/SLA.0b013e31827b947a](#)]
- 51 **Cheung TT**, Ng KK, Poon RT, Chan SC, Lo CM, Fan ST. A case of laparoscopic hepatectomy for recurrent hepatocellular carcinoma. *World J Gastroenterol* 2010; **16**: 526-530 [PMID: [20101784](#) DOI: [10.3748/wjg.v16.i4.526](#)]
 - 52 **Cheung TT**, Poon RT, Dai WC, Chok KS, Chan SC, Lo CM. Pure Laparoscopic Versus Open Left Lateral Sectionectomy for Hepatocellular Carcinoma: A Single-Center Experience. *World J Surg* 2016; **40**: 198-205 [PMID: [26316115](#) DOI: [10.1007/s00268-015-3237-8](#)]
 - 53 **Siddiqi NN**, Abuawwad M, Halls M, Rawashdeh A, Giovino F, Aljaioussi A, Wicherts D, D'Hondt M, Hilal MA. Laparoscopic right posterior sectionectomy (LRPS): surgical techniques and clinical outcomes. *Surg Endosc* 2018; **32**: 2525-2532 [PMID: [29101556](#) DOI: [10.1007/s00464-017-5958-2](#)]
 - 54 **Chan AC**, Poon RT, Chok KS, Cheung TT, Chan SC, Lo CM. Feasibility of laparoscopic re-resection for patients with recurrent hepatocellular carcinoma. *World J Surg* 2014; **38**: 1141-1146 [PMID: [24305932](#) DOI: [10.1007/s00268-013-2380-3](#)]
 - 55 **Starzl TE**, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation Of The Liver In Humans. *Surg Gynecol Obstet* 1963; **117**: 659-676 [PMID: [14100514](#)]
 - 56 **Majno PE**, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. *Hepatology* 2000; **31**: 899-906 [PMID: [10733546](#) DOI: [10.1053/he.2000.5763](#)]
 - 57 **Vennarecci G**, Ettorre GM, Antonini M, Santoro R, Maritti M, Tacconi G, Spoleini D, Tessitore L, Perracchio L, Visco G, Puoti C, Santoro E. First-line liver resection and salvage liver transplantation are increasing therapeutic strategies for patients with hepatocellular carcinoma and child a cirrhosis. *Transplant Proc* 2007; **39**: 1857-1860 [PMID: [17692633](#) DOI: [10.1016/j.transproceed.2007.05.073](#)]
 - 58 **Kim BW**, Park YK, Kim YB, Wang HJ, Kim MW. Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: feasibility of the Milan criteria and operative risk. *Transplant Proc* 2008; **40**: 3558-3561 [PMID: [19100437](#) DOI: [10.1016/j.transproceed.2008.03.175](#)]
 - 59 **Chan DL**, Alzahrani NA, Morris DL, Chua TC. Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma. *J Gastroenterol Hepatol* 2014; **29**: 31-41 [PMID: [24117517](#) DOI: [10.1111/jgh.12399](#)]
 - 60 **Bhangui P**, Allard MA, Vibert E, Cherqui D, Pelletier G, Cunha AS, Guettier C, Vallee JC, Saliba F, Bismuth H, Samuel D, Castaing D, Adam R. Salvage Versus Primary Liver Transplantation for Early Hepatocellular Carcinoma: Do Both Strategies Yield Similar Outcomes? *Ann Surg* 2016; **264**: 155-163 [PMID: [26649581](#) DOI: [10.1097/SLA.0000000000001442](#)]
 - 61 **Yadav DK**, Chen W, Bai X, Singh A, Li G, Ma T, Yu X, Xiao Z, Huang B, Liang T. Salvage Liver Transplant versus Primary Liver Transplant for Patients with Hepatocellular Carcinoma. *Ann Transplant* 2018; **23**: 524-545 [PMID: [30072683](#) DOI: [10.12659/AOT.908623](#)]
 - 62 **Yamashita Y**, Yoshida Y, Kurihara T, Itoh S, Harimoto N, Ikegami T, Yoshizumi T, Uchiyama H, Shirabe K, Maehara Y. Surgical results for recurrent hepatocellular carcinoma after curative hepatectomy: Repeat hepatectomy versus salvage living donor liver transplantation. *Liver Transpl* 2015; **21**: 961-968 [PMID: [25772591](#) DOI: [10.1002/lt.24111](#)]
 - 63 **Yong CC**, Tsai MC, Lin CC, Wang CC, Lu SN, Hung CH, Hu TH, Chen CL. Comparison of Salvage Living Donor Liver Transplantation and Local Regional Therapy for Recurrent Hepatocellular Carcinoma. *World J Surg* 2016; **40**: 2472-2480 [PMID: [27194562](#) DOI: [10.1007/s00268-016-3559-1](#)]
 - 64 **Zhang X**, Li C, Wen T, Peng W, Yan L, Yang J. Treatment for intrahepatic recurrence after curative resection of hepatocellular carcinoma: Salvage liver transplantation or re-resection/radiofrequency ablation? *Int J Surg* 2017; **46**: 178-185 [PMID: [28890407](#) DOI: [10.1016/j.ijsu.2017.09.001](#)]
 - 65 **Zheng J**, Cai J, Tao L, Kirih MA, Shen Z, Xu J, Liang X. Comparison on the efficacy and prognosis of different strategies for intrahepatic recurrent hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis. *Int J Surg* 2020; **83**: 196-204 [PMID: [32980518](#) DOI: [10.1016/j.ijsu.2020.09.031](#)]
 - 66 **Belghiti J**, Cortes A, Abdalla EK, Régimbeau JM, Prakash K, Durand F, Sommacale D, Dondero F, Lesurtel M, Sauvanet A, Farges O, Kianmanesh R. Resection prior to liver transplantation for hepatocellular carcinoma. *Ann Surg* 2003; **238**: 885-925; discussion 892 [PMID: [14631225](#) DOI: [10.1097/01.sla.0000098621.74851.65](#)]
 - 67 **Rhu J**, Kim JM, Choi GS, Kwon CHD, Joh JW. Continuing five or more locoregional therapies before living donor salvage liver transplantation for hepatocellular carcinoma is related to poor recurrence-free survival. *Ann Surg Treat Res* 2018; **95**: 152-160 [PMID: [30182022](#) DOI: [10.4174/astr.2018.95.3.152](#)]
 - 68 **Lee S**, Hyuck David Kwon C, Man Kim J, Joh JW, Woon Paik S, Kim BW, Wang HJ, Lee KW, Suh KS, Lee SK. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation. *Liver Transpl* 2014; **20**: 1057-1063 [PMID: [24862741](#) DOI: [10.1002/lt.23919](#)]
 - 69 **Lee SG**. Salvage living-donor liver transplantation to previously hepatectomized hepatocellular carcinoma patients: is it a reasonable strategy? *Hepatobiliary Pancreat Dis Int* 2013; **12**: 10-11 [PMID: [23392794](#) DOI: [10.1016/s1499-3872\(13\)60001-6](#)]
 - 70 **Fuks D**, Dokmak S, Paradis V, Diouf M, Durand F, Belghiti J. Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. *Hepatology* 2012; **55**: 132-140 [PMID: [21932387](#) DOI: [10.1002/hep.24680](#)]
 - 71 **Zhang HM**, Jiang WT, Pan C, Deng YL, Zheng H, Shen ZY. Milan criteria, University of California, San Francisco, criteria, and model for end-stage liver disease score as predictors of salvage liver transplantation. *Transplant Proc* 2015; **47**: 438-444 [PMID: [25769587](#) DOI: [10.1016/j.transproceed.2014.10.046](#)]
 - 72 **de Haas RJ**, Lim C, Bhangui P, Salloum C, Compagnon P, Feray C, Calderaro J, Luciani A, Azoulay D. Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: An intention-to-treat analysis. *Hepatology* 2018; **67**: 204-215 [PMID: [28806477](#) DOI: [10.1002/hep.29468](#)]
 - 73 **Liu F**, Wei Y, Wang W, Chen K, Yan L, Wen T, Zhao J, Xu M, Li B. Salvage liver transplantation for recurrent hepatocellular carcinoma within UCSF criteria after liver resection. *PLoS One* 2012; **7**: e48932 [PMID: [23145027](#) DOI: [10.1371/journal.pone.0048932](#)]

- 10.1371/journal.pone.0048932]
- 74 **Wang P**, Pu Y, Li H, Shi B, Zheng S, Zhong L. Prognosis for recipients with hepatocellular carcinoma of salvage liver transplantation versus those of primary liver transplantation: a retrospective single-center study. *Springerplus* 2016; **5**: 1809 [PMID: 27818858 DOI: 10.1186/s40064-016-3441-5]
 - 75 **Qu W**, Zhu ZJ, Sun LY, Wei L, Liu Y, Zeng ZG. Salvage liver transplantation for hepatocellular carcinoma recurrence after primary liver resection. *Clin Res Hepatol Gastroenterol* 2015; **39**: 93-97 [PMID: 25150375 DOI: 10.1016/j.clinre.2014.07.006]
 - 76 **Hu Z**, Zhou J, Xu X, Li Z, Zhou L, Wu J, Zhang M, Zheng S. Salvage liver transplantation is a reasonable option for selected patients who have recurrent hepatocellular carcinoma after liver resection. *PLoS One* 2012; **7**: e36587 [PMID: 22574187 DOI: 10.1371/journal.pone.0036587]
 - 77 **Lin CC**, Elsarawy AM, Li WF, Lin TL, Yong CC, Wang SH, Wang CC, Kuo FY, Cheng YF, Chen CL. Liver Transplantation for High Risk Hepatocellular Carcinoma After Liver Resection: A Sequential or Salvage Approach? *Ann Transplant* 2017; **22**: 602-610 [PMID: 28993607 DOI: 10.12659/aot.905779]
 - 78 **Harimoto N**, Yoshida Y, Kurihara T, Takeishi K, Itoh S, Harada N, Tsujita E, Yamashita YI, Uchiyama H, Soejima Y, Ikegami T, Yoshizumi T, Kawanaka H, Ikeda T, Shirabe K, Saeki H, Oki E, Kimura Y, Maehara Y. Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma. *Transplant Proc* 2015; **47**: 703-704 [PMID: 25819732 DOI: 10.1016/j.transproceed.2014.09.178]
 - 79 **Yoshizumi T**, Ikegami T, Yoshiya S, Motomura T, Mano Y, Muto J, Ikeda T, Soejima Y, Shirabe K, Maehara Y. Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma. *Hepatol Res* 2013; **43**: 709-716 [PMID: 23190306 DOI: 10.1111/hepr.12016]
 - 80 **Chan AC**, Chan SC, Chok KS, Cheung TT, Chiu DW, Poon RT, Fan ST, Lo CM. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? *Liver Transpl* 2013; **19**: 411-419 [PMID: 23447460 DOI: 10.1002/lt.23605]
 - 81 **Lim C**, Shinkawa H, Hasegawa K, Bhangu P, Salloum C, Gomez Gavara C, Lahat E, Omichi K, Arita J, Sakamoto Y, Compagnon P, Feray C, Kokudo N, Azoulay D. Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: An intent-to-treat analysis. *Liver Transpl* 2017; **23**: 1553-1563 [PMID: 28945955 DOI: 10.1002/lt.24952]
 - 82 **Kostakis ID**, Machairas N, Prodromidou A, Stamopoulos P, Garoufalia Z, Fouzas I, Sotiropoulos GC. Comparison Between Salvage Liver Transplantation and Repeat Liver Resection for Recurrent Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. *Transplant Proc* 2019; **51**: 433-436 [PMID: 30879559 DOI: 10.1016/j.transproceed.2019.01.072]
 - 83 **Sun HC**, Zhou J, Wang Z, Liu X, Xie Q, Jia W, Zhao M, Bi X, Li G, Bai X, Ji Y, Xu L, Zhu XD, Bai D, Chen Y, Dai C, Guo R, Guo W, Hao C, Huang T, Huang Z, Li D, Li T, Li X, Liang X, Liu J, Liu F, Lu S, Lu Z, Lv W, Mao Y, Shao G, Shi Y, Song T, Tan G, Tang Y, Tao K, Wan C, Wang G, Wang L, Wang S, Wen T, Xing B, Xiang B, Yan S, Yang D, Yin G, Yin T, Yin Z, Yu Z, Zhang B, Zhang J, Zhang S, Zhang T, Zhang Y, Zhang A, Zhao H, Zhou L, Zhang W, Zhu Z, Qin S, Shen F, Cai X, Teng G, Cai J, Chen M, Li Q, Liu L, Wang W, Liang T, Dong J, Chen X, Wang X, Zheng S, Fan J; Alliance of Liver Cancer Conversion Therapy, Committee of Liver Cancer of the Chinese Anti-Cancer Association. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). *Hepatobiliary Surg Nutr* 2022; **11**: 227-252 [PMID: 35464283 DOI: 10.21037/hbsn-21-328]
 - 84 **Guerrini GP**, Gerunda GE, Montalti R, Ballarin R, Cautero N, De Ruvo N, Spaggiari M, Di Benedetto F. Results of salvage liver transplantation. *Liver Int* 2014; **34**: e96-e104 [PMID: 24517642 DOI: 10.1111/liv.12497]
 - 85 **Yoon YI**, Song GW, Lee S, Moon D, Hwang S, Kang WH, Cho HD, Ha SM, Kim MJ, Kim SH, Na BG, Yang G, Min Kim S, Hyun Shim J, Park JI. Salvage living donor liver transplantation versus repeat liver resection for patients with recurrent hepatocellular carcinoma and Child-Pugh class A liver cirrhosis: A propensity score-matched comparison. *Am J Transplant* 2022; **22**: 165-176 [PMID: 34383368 DOI: 10.1111/ajt.16790]
 - 86 **Faber W**, Seehofer D, Neuhaus P, Stockmann M, Denecke T, Kalmuk S, Warnick P, Bahra M. Repeated liver resection for recurrent hepatocellular carcinoma. *J Gastroenterol Hepatol* 2011; **26**: 1189-1194 [PMID: 21410751 DOI: 10.1111/j.1440-1746.2011.06721.x]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

